SRF Awards Research Grant to Heller Lab of Neuroepigenetics
https://pixabay.com/en/dna-microscopic-cell-gene-helix-1903319/

SRF Awards Research Grant to Heller Lab of Neuroepigenetics

In a recent press release, the SynGAP Research Fund (SRF) shared that the Heller Laboratory of Neuroepigenetics would receive a $130,000 research grant. The fund, which will be granted over…

Continue Reading SRF Awards Research Grant to Heller Lab of Neuroepigenetics
VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
source: pixabay.com

VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat

In November 2020, Viking Therapeutics ("Viking") shared insight into their metabolic disease program. According to Greg Zante, the Senior VP (SVP) of Finance for Viking, the company's treatment VK2809, licensed…

Continue Reading VK2809 for NASH Significantly Reduces LDL Cholesterol, Liver Fat
Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
source: pixabay.com

Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice

     The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…

Continue Reading Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children
source: pixabay.com

Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children

According to an announcement from the FH Foundation, data from the FH Foundation’s CASCADE FH Registry, published in The Journal of Pediatrics, has determined that children living with familial hypercholesterolemia regularly…

Continue Reading Study: Familial Hypercholesterolemia is Diagnosed Late and Under-treated in US Children
OTL-200 for Metachromatic Leukodystrophy Investigational New Drug Application Gets Approved
qimono / Pixabay

OTL-200 for Metachromatic Leukodystrophy Investigational New Drug Application Gets Approved

  In a recent press release, gene therapy company Orchard Therapeutics ("Orchard") announced that the FDA approved Orchard's Investigational New Drug (IND) application for OTL-200. This gene therapy solution is…

Continue Reading OTL-200 for Metachromatic Leukodystrophy Investigational New Drug Application Gets Approved
Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS
source: pixabay.com

Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS

  According to a report in BioPharma Dive, Brainstorm Therapeutics, a New York biotechnology company, said that while its NurOwn therapy for amyotrophic lateral sclerosis (ALS) appeared to have a…

Continue Reading Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS
Avacopan Better than Prednisone for Patients with AAV, Study Shares
freegr / Pixabay

Avacopan Better than Prednisone for Patients with AAV, Study Shares

Recently, the American College of Rheumatology (ACR) virtually held ACR Convergence 2020, the organization's annual meeting. At the meeting, researchers shared new insights in the realm of rheumatology; these were…

Continue Reading Avacopan Better than Prednisone for Patients with AAV, Study Shares

Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference

A recent article in BioSpace highlighted presentations by Twist Bioscience, a rapidly growing genomic and synthetic biology company. Twist presented its product line at the virtual 2020 Annual Meeting of…

Continue Reading Twist Bioscience Gives Impressive Presentation at the Virtual American Society for Human Genetics 2020 Annual Conference
Stem Cells Could Cure the Most Common Cause of Irreversible Blindness 
source: pixabay.com

Stem Cells Could Cure the Most Common Cause of Irreversible Blindness 

As reported in Medical Xpress; Fight for Sight, a charity in the UK dedicated to vision, has an exciting announcement for people with macular diseases: they have just granted funding…

Continue Reading Stem Cells Could Cure the Most Common Cause of Irreversible Blindness 
ICYMI: EC Approves OXLUMO for Patients with Primary Hyperoxaluria Type 1
JillWellington / Pixabay

ICYMI: EC Approves OXLUMO for Patients with Primary Hyperoxaluria Type 1

  In late November, RNAi therapeutics company Alnylam Pharmaceuticals ("Alnylam") announced that its therapy OXLUMO (Lumasiran) received approval from the European Commission (EC) for both pediatric and adult patients with…

Continue Reading ICYMI: EC Approves OXLUMO for Patients with Primary Hyperoxaluria Type 1
Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy
source: pixabay.com

Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy

Colette Wheeler is one of four siblings, and although each had only a 50/50 chance of inheriting the genetic mutation that leads to facioscapulohumeral muscular dystrophy (FSHD), all of them…

Continue Reading Love, Work, Progress, and Community in Facioscapulohumeral Muscular Dystrophy